Corona Remedies Ltd., fresh from a blockbuster IPO, announced a big boost in its production capacity at the Bhayla plant near Ahmedabad.
IPO Highlights
The company listed on December 15, 2025, at a 38% premium, opening at ₹1,470 per share versus the ₹1,062 issue price. The entire ₹655.37 crore offering was an Offer‑for‑Sale (OFS) and was subscribed 137 times, driven mainly by institutional investors.
New Production Capacity
From December 22, 2025, Corona Remedies began extra commercial production of tablets and capsules at Bhayla. The plant’s installed capacity rose by 240 million units, taking total annual output to 1.09 billion units. Utilisation is already high, at 93.58% as of March 2025, and the expansion was funded completely from internal accruals.
- Capacity increase: +240 million units
- New total capacity: 1.09 billion units per year
- Funding: internal cash reserves
- Current utilisation: 93.58%
Why It Matters for Investors
The expansion positions Corona Remedies to meet rising demand for its branded formulations, which cover women's health, cardio‑diabetes, pain management and urology. Higher in‑house production can improve margins and reduce reliance on third‑party manufacturers.
For shareholders, the move signals confidence from management and could translate into stronger earnings growth as the company scales up.
Remember, this is perspective, not prediction. Do your own research before making any investment decisions.